4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-26-122272
Chief Executive Officer sold 10,020 shares at $46.78 ($468,736)
- Chief Executive Officer acquired 19,687 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Kulkarni Samarth · Chief Executive Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-03-20 | Exercise or conversion : show line 1 in the form | +19,687 | 265,521 | D | ||
| 2026-03-23 | Sale : show line 2 in the form | −10,020 | $46.78 | $468,736 | 255,501 | D |
| Open-market sales · 10,020 sh · avg $46.78 · $468,736 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-03-20 | Grant or award : show line 3 in the form Stock Option (Right to Buy) | +114,249 | 114,249 | D |
| 2026-03-20 | Grant or award : show line 4 in the form Restricted Stock Units | +81,875 | 81,875 | D |
| 2026-03-20 | Exercise or conversion : show line 5 in the form Restricted Stock Units | −19,687 | 39,375 | D |
Loading xslF345X06/ownership.xml…